We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PHANTOM-S
Previous Study | Return to List | Next Study

PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study (PHANTOM-S)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01382862
Recruitment Status : Completed
First Posted : June 27, 2011
Last Update Posted : September 15, 2015
Sponsor:
Collaborators:
Berlin Firebrigade
MEYTEC GmbH
B.R.A.H.M.S GmbH ThermoFisher Scientific
Federal Ministry of Education and Research via Center for Stroke Research Berlin (CSB)
European Union
Berlin Technology Foundation (EFRE)
The Volkswagen Foundation
German Research Foundation
Information provided by:
Charite University, Berlin, Germany

Brief Summary:
The purpose of this prospective study in acute ischemic stroke patients is to compare alarm-to-needle time during randomly allocated periods with and without availability of a specially staffed ambulance equipped with computed tomography (CT) and point-of care diagnostics. The investigators hypothesize that compared to regular care the investigators will reduce alarm-to-needle time by a minimum of 20 minutes by implementation of the stroke emergency mobile unit.

Condition or disease Intervention/treatment Phase
Acute Stroke Other: Stroke Emergency Mobile Unit (STEMO) Phase 2

Detailed Description:

Time from symptom onset is crucial for the effectiveness of intravenous thrombolysis in acute ischemic stroke patients. Many patients receive tissue Plasminogen Activator (tPA) with considerable delay. The investigators developed an ambulance equipped with a CT-scanner, point-of-care laboratory, teleradiological support and an emergency trained neurologist on board. In the Pre-Hospital Acute Neurological Therapy and Optimization of Medical care in Stroke patients (PHANTOM-S)-study the investigators aim at a reduction of the current alarm-to-needle time by pre-hospital use of tissue Plasminogen Activator in an ambulance.

The investigators hypothesize that compared to regular care we will reduce alarm-to-needle time by a minimum of 20 minutes by implementation of the stroke emergency mobile unit (STEMO).

This is a prospective study comparing randomly allocated periods with and without STEMO availability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 614 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study
Study Start Date : May 2011
Actual Primary Completion Date : January 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Regular Care
Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
Active Comparator: Stroke Emergency Unit Mobile (STEMO)
The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
Other: Stroke Emergency Mobile Unit (STEMO)
Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
Other Name: pre-hospital thrombolysis




Primary Outcome Measures :
  1. alarm-to-needle time [ Time Frame: day 1 ]
    Primary endpoint of the study is the time between activation of the emergency medical service and initiation of thrombolysis (alarm-to-needle time).


Secondary Outcome Measures :
  1. Functional outcomes [ Time Frame: three months after symptom onset ]
    Functional outcome of patients will be assessed via modified Rankin Scale (mRS) during telephone follow-up after three months and mortality

  2. other times [ Time Frame: day 1 ]
    Alarm-to-imaging Imaging-to-needle Alarm-to-point-of-care laboratory diagnostics (International Normalized Ratio (INR), platelet count) Alarm-to-INR normalization (<1.5) in cases of intracerebral hemorrhage (ICH) and INR>1.7

  3. Costs effectiveness will be assessed [ Time Frame: 15 months (coinciding with the anticipated date of the completion of the last follow-up) ]
  4. Proportion of stroke patients receiving tissue Plasminogen Activator (tPA) [ Time Frame: day 1 ]
    Proportion of stroke patients receiving tPA will be assessed and compared between regular care and STEMO.

  5. Special referral [ Time Frame: day 1 ]

    Proportion of patients referred to specialized centres in case of:

    Occlusion of distal carotid / proximal middle cerebral artery Space occupying cerebellar ICH (at least 6 mL) Intraventricular haemorrhage (>/= 1 ventricle filled with blood)


  6. symptomatic intracerebral hemorrhage [ Time Frame: 36 hours after symptom onset ]
    symptomatic intracerebral hemorrhage (sICH) will be assessed according to European Cooperative Acute Stroke Study (ECASS) III and National Institute of Neurological Disorders and Stroke (NINDS) definition

  7. Serious adverse events [ Time Frame: up to 3 months ]
    Number of Serious Adverse Events (SAE) according to good clinical practice (GCP) classification

  8. Mortality [ Time Frame: up to three months ]
    In-hospital mortality (i.e. 7-days-mortality = primary safety outcome; safety analyses will include patients who received tissue Plasminogen Activator during the pilot phase of the study) and mortality three months after stroke will be assessed in stroke patients.


Other Outcome Measures:
  1. Proportions of patients treated in time intervals from onset [ Time Frame: day 1 ]

    According to time intervals 0-90, 91-180, 181-270 minutes as used in the pooled analysis of randomized controlled iv tPA trials(K. Lees et al., Lancet, 2010).

    This outcome was specified before completion of data collection and will be used for cost-effectiveness analyses.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients whose emergency call prompted the suspicion of stroke within 4 hours of symptom onset or with undetermined time of onset in the dispatch center
  • Informed consent for documentation and follow-up provided by patients or legal representatives

Exclusion Criteria:

  • age < 18 years
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01382862


Locations
Layout table for location information
Germany
Charite - Universitätsmedizin Berlin
Berlin, Germany, 10117
Sponsors and Collaborators
Charite University, Berlin, Germany
Berlin Firebrigade
MEYTEC GmbH
B.R.A.H.M.S GmbH ThermoFisher Scientific
Federal Ministry of Education and Research via Center for Stroke Research Berlin (CSB)
European Union
Berlin Technology Foundation (EFRE)
The Volkswagen Foundation
German Research Foundation
Investigators
Layout table for investigator information
Principal Investigator: Heinrich Audebert, Prof Charite University, Berlin, Germany
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Heinrich Audebert/ Prof. Dr. med., Charité - Universitätsmedizin Berlin, Center for Stroke Research Berlin
ClinicalTrials.gov Identifier: NCT01382862    
Other Study ID Numbers: PHANTOM-S
First Posted: June 27, 2011    Key Record Dates
Last Update Posted: September 15, 2015
Last Verified: February 2013
Keywords provided by Charite University, Berlin, Germany:
acute ischemic stroke
thrombolysis
prehospital
emergency medicine
suspected acute stroke
telemedicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases